Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

Clinicaltrial registered30 Oct 2026

Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

30 Oct 2026: Trial registered · A Mass Balance Study on [14C]Levornidazole Disodium Phosphate for Injection in Healthy Chinese Adult Male Subjects. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
30 Oct 2026
Title
A Mass Balance Study on [14C]Levornidazole Disodium Phosphate for Injection in Healthy Chinese Adult Male Subjects
Conditions
Mass Balance Study
Phase
Phase 1
Study Type
Interventional
Status
Completed
Countries
China
Country
China
Reference
NCT07906197
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd in our registers.

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.